FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CH
obligations may continue. See	
Instruction 1(b).	Filed nursuant to Se

## ANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Main David					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol AQUINOX PHARMACEUTICALS, INC									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)	/E	irst)	(Middle)		- LAC	AQXP ]  X Director 10% Owner  X Officer (give title below) below)												pecify		
C/O AQUINOX PHARMACEUTICALS INC. 450 - 887 GREAT NORTHERN WAY						3. Date of Earliest Transaction (Month/Day/Year) 03/12/2015								President and CEO						
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)  VANCO	UVER A	1	V5T 4T5											X	<b>'</b>					
(City)	(S	tate)	(Zip)												Person					
		Tab	le I - Nor	ı-Deriv	vativ	e Se	curities	s Ac	quired, D	isp	osed o	f, or Be	neficia	lly O	wned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution [			Code (Ins	action Disposed		ties Acquiro I Of (D) (Ins		4 and Securitie Benefici Owned F		s illy ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	<i>,</i>	Amount	(A) oi (D)	Price	т	Reported Transact Instr. 3 a	tion(s)			(Instr. 4)		
		-							uired, Dis , options					y Ow	ned					
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Transaction Code (Instr. 3)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 a	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares	1						
Stock Option (Right to Buy)	\$12.03	03/12/2015			A		65,000		(1)	03/	/11/2025	Common Stock	65,000	\$	0.00	65,000	)	D		

## **Explanation of Responses:**

1. The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of the vesting commencement date and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date.

## Remarks:

/s/ David J. Main

03/16/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.